AdipoGen Life Sciences Bafilomycin A1

Wednesday, 14 February, 2024 | Supplied by: Sapphire Bioscience

The bafilomycins are a family of macrolide antibiotics produced from a variety of Streptomycetes which exhibit a wide range of biological activity, including anti-tumour, anti-parasitic, anti-viral, anti-fungal and immunosuppressant activity. Bafilomycin A1 selectively inhibits vacuolar H+-ATPases and is a potent inhibitor of cellular autophagy where it either blocks autophagosome-lysosome fusion or blocks lysosomal degradation.

Bafilomycin interferes with autophagy by inhibiting the acidification of the lysosome through its interaction with V-ATPase. Lack of lysosomal acidification prevents the activity of lysosomal proteases like cathepsins so that engulfed cargo can no longer be degraded.

Bafilomycin A1 has been described to have several other biological activities: it induces apoptosis or acts as a K+ ionophore; induces mitochondrial swelling in the presence of K+ ions; stimulates the oxidation of pyrimidine nucleotides and uncouple oxidative phosphorylation; inhibits V‐ATPase activity; inhibits SARS-CoV-2 replication; inhibits the growth of tumour cells by blocking the acidification of lysosomes; promotes the clearance of accumulated cellular waste from lysosomes; and helps to protect neurons from damage.

AdipoGen Life Sciences’ Bafilomycin A1 is distributed in Australia and New Zealand by Sapphire Bioscience.

Phone: 02 9698 2022
Related Products

Biosensis MAP2 antibodies

Biosensis's validated MAP2 antibodies are designed to help users identify MAP2, whether they...

Bio-Rad Laboratories Celselect Slides validated antibodies for rare cell and CTC enumeration

The antibodies are specific to CTC surface markers to enable the sensitive and specific...

Microbiologics UV-BioTAG QC microorganisms for quality control testing

UV-BioTAG, a line of reference strains containing green fluorescent protein (GFP) markers, makes...

  • All content Copyright © 2024 Westwick-Farrow Pty Ltd